RC
TBPH icon

Rangeley Capital’s Theravance Biopharma TBPH Stock Holding History

Rangeley Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.67M Buy
+103,000
New +$1.82M 1.62% 21
2025
Q3 		– Sell
-33,729
Closed -$372K – 142
2025
Q2 		$372K Buy
+33,729
New +$328K 0.44% 38

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rangeley Capital's TBPH Position: Q1 2026 in Review

Rangeley Capital opened a new position in Theravance Biopharma (TBPH) in Q1 2026: 103,000 shares worth $1.67M. The stake represents 1.62% of the portfolio and ranks #21 among its holdings. This is a return to the name: Rangeley Capital previously reported a position in TBPH as recently as Q2 2025.

Rangeley Capital first reported a position in TBPH in Q2 2025 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Rangeley Capital held 103,000 shares of Theravance Biopharma worth $1.67M as of Q1 2026.
  • Theravance Biopharma was a new Rangeley Capital position in Q1 2026.
  • Theravance Biopharma made up 1.62% of Rangeley Capital's portfolio in Q1 2026, its #21 holding.
  • Rangeley Capital first reported a position in Theravance Biopharma in Q2 2025 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.